伊尼妥单抗后线治疗HER2阳性晚期乳腺癌1例

Posterior line treatment with Inetetamab for HER2-positive advanced breast cancer:a case report

人表皮生长因子受体2(HER2)阳性乳腺癌是侵袭性较强的乳腺癌亚型,占所有乳腺癌的20%,其预后差且复发率高,在抗HER2靶向药物面世之前,HER2阳性乳腺癌是预后最差的乳腺癌分型之一。抗HER2靶向治疗药物的出现降低了早期HER2阳性乳腺癌患者的复发率,显著延缓了HER2阳性晚期乳腺癌患者病情进展,并带来生存获益。本文报道1例肝、骨、肺多发转移的HER2阳性晚期乳腺癌患者,肿瘤复发后经历三线化疗联合抗HER2靶向治疗,经伊尼妥单抗联合吡咯替尼及白蛋白紫杉醇化疗方案四线治疗后肺转移灶明显缩小,评估最佳疗效为部分缓解,患者已获得超过11个月无进展生存时间,在四线治疗获得如此长的疾病控制时间,结果振奋人心。

Human epidermal growth factor receptor-2(HER2)positive breast cancer is a more aggressive subtype of breast cancer with poor prognosis and high recurrence rate,accounting for 20%of all breast cancers.Prior to the availability of anti-HER2-targeting drugs,HER2-positive breast cancer was one of the breast cancer types with the worst prognosis.In recent years,a series of anti-HER2-targeted therapies have been developed to reduce the recurrence rate in patients with early HER2 positive breast cancer,and remarkblely delay the progression of HER2-positive breast cancer and bring survival benefits.This article reports a case of HER2-positive advanced breast cancer with multiple liver,bone,and lung metastases.After tumor recurrence,she underwent three-line chemotherapy combined with anti-HER2 targeting therapy.The patients'lung lesion was significantly reduced after four-line treatment with Inetetamab combined with Pyrotinib and chemotherapy.The best outcome was assessed as partial response,and the patient achieved a survival benefit of more than 11 months.The results for such a long period of disease control achieved with fourth-line therapy are encouraging.